Zevra's Turnaround: Guideline-Backed Momentum, a Clean Balance Sheet, and a Europe Catalyst

The FDX divestiture and NPC clinical-practice-guideline inclusion mark a decisive shift from turnaround to growth story — with the balance sheet to prove it.

ZVRA · Earnings Call · 2026-05-06

A Strategic Pivot, Executed in One Quarter

Zevra Therapeutics used Q1 2026 to shed its past. The sale of the FDX portfolio to CommAv Therapeutics for $50 million, the early retirement of all outstanding debt, and the relocation of corporate headquarters to Boston collectively paint a picture of a company no longer managing legacy assets but executing a focused rare-disease plan. CFO Justin Renz was blunt about the new footing: “We are now debt free, strategically positioned for growth, supported by a clean balance sheet.” — Justin Renz, Chief Financial Officer (CFO) · 2026-05-06 The financials confirm the inflection. The company swung from a net loss of $3.1 million a year ago to net income of $37.9 million, with revenue up 78% to $36.2 million. Even excluding the one-time gain on the FDX sale and the debt-extinguishment expense, net income was $11.5 million — the company's first sustainable quarter of profitability by its own framing. Total revenue of $36M, +78% YoY, driven by $24.6M in MyPlifer U.S. sales and $10.2M in global EAP net reimbursements.

The Guidelines Catalyst: Validation at the KOL Level

The most important commercial development isn't on the income statement yet. MyPlifer was added to the NPC clinical practice guidelines, published in the Journal of Inherited Metabolic Disease — the first update since 2018. CEO Neil McFarlane framed it as a sea change for physician engagement:

It really reinforces the NPC severity scale as the tool that shows disease progression, the genetic testing as a key endpoint and diagnostic tool, and the complexity of the disease.
Neil F. McFarlane, Chief Executive Officer (CEO) · 2026-05-06

Chief Commercial Officer Josh Schafer emphasized the practical effect: “These are the opinions of a select group of key opinion leaders that we are now able to use and communicate and help build confidence and consistency in the way that some HCPs who might not be as familiar with NPC can now use this as a consistent guide for their treatment.” — Joshua M. Schafer, Commercial/Medical Executive · 2026-05-06 The company's own clinical practice guidelines inclusion, combined with genetic testing collaborations (and a custom AI-driven targeting model), is expanding the prescriber base beyond centers of excellence into community-based physicians. The GeneDx collaboration, highlighted on the prior call, targets diagnosis confirmation within weeks: “from the time there's a test to results available, it's estimated that physicians would know those results within about 3 weeks.” — Joshua Schafer, Commercial Leader · 2026-03-09 Management's message is consistent: early diagnosis is the key to pulling more of the ~900 estimated prevalent U.S. NPC patients into treatment.

Europe: The EAP as a Leading Indicator

The global EAP numbers continue to build — 122 patients enrolled across geographies at quarter end, with France stable at roughly $10 million net per year. The EMA marketing authorization application is under review; Zevra submitted its responses to the 120-day list within the 90-day clock stop, leaving management confident there were no surprises. “Since we have not actually seen any new questions that we did not see that we were able to then provide... it is the totality of the data” — Neil F. McFarlane, Chief Executive Officer (CEO) · 2026-05-06 that management expects to carry the day. With an estimated 1,100 NPC patients in Europe and higher diagnosis rates (miglustat's prior approval created physician awareness), the EAP enrollment trajectory is a meaningful leading indicator for post-approval commercial concentration.

The VEDS Option and the Tape

The DISCOVER trial for vascular Ehlers-Danlos syndrome (VEDS) continues to enroll — 62 patients total, with 10 added in Q1, and 2 of 28 events confirmed toward the interim analysis. No approved therapy exists for VEDS in the U.S., and the FDA Type C meeting in Q1 opens the door to potential development acceleration in H2. The expand access narrative now has the medical exception pathway as a backstop for the 31% of covered lives not yet on formulary — with 69% covered and reimbursement consistently achieved through exceptions. The balance sheet tells the story: Net cash of $96M, up 487% YoY after FDX proceeds and debt payoff. Prior-quarter commentary reinforces how far the company has come — in the March 2026 call, McFarlane described the annual enrollment cadence: “52 patients in our first full year post launch, we think is a really great number moving forward for us... it is removing the barriers that we've seen out there.” — Neil McFarlane, Chief Executive Officer · 2026-03-09 The Q1 2026 launch performance — 170 enrollment forms, roughly half the diagnosed U.S. NPC population — appears consistent with that cadence. The market is taking notice. ZVRA returned +25.3% over the last 90 trading days (up 17 weeks virtually uninterrupted), though it sits ~19.5% below its July 8 peak of $14.75. With Price-to-Revenue at 4.5x, down 55% YoY, the market seems to be pricing in execution risk on Europe and VEDS rather than the U.S. launch — which is exactly the asymmetry this report highlights.